Secondary Logo

Journal Logo

Clinical Science

The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor–Resistant Clinical Isolates

Ray, Neelanjana PhD*; Li, Tianbo PhD†,‡; Lin, Zeyu MSc*; Protack, Tricia BSc; van Ham, Petronella Maria BSc§; Hwang, Carey MD*,‖; Krystal, Mark PhD†,‡; Nijhuis, Monique PhD; Lataillade, Max DO, MPH†,‡; Dicker, Ira PhD†,‡

Author Information
JAIDS Journal of Acquired Immune Deficiency Syndromes: May 01, 2017 - Volume 75 - Issue 1 - p 52-60
doi: 10.1097/QAI.0000000000001304



HIV and AIDS remain a global health issue despite the success of combination antiretroviral (ARV) therapy.1 Life-long management of HIV-1 infection requires sequential ARV therapies, preferably with simple and convenient regimens containing at least 2 fully active agents.2,3 ARV treatment options, particularly for treatment-experienced patients, may be limited by treatment-emergent or transmitted resistance, adverse events, drug–drug interactions, or regimen complexity.2–4 Therefore, novel ARVs are needed that could potentially change HIV-1 treatment paradigms. Such regimens would benefit from components with novel mechanisms of action, unique resistance profiles, good long-term tolerability, and manageable drug–drug interactions.

HIV-1 maturation is the final step in the viral life cycle and involves multiple cleavages by the viral protease (PR) at discrete sites in HIV-1 Gag, leading to a profound morphologic rearrangement of the virion and condensation of the viral capsid (CA) core with concomitant release of infectious virus from the host cell.5,6 Disrupting Gag cleavage at individual sites results in the production of noninfectious HIV-1 particles,7,8 suggesting that inhibition of HIV-1 maturation might represent a novel therapeutic approach. Bevirimat (BVM) was a first-generation maturation inhibitor (MI) that inhibited the last proteolytic cleavage event in Gag, between the p24 CA protein and spacer peptide 1 (SP1), thereby resulting in the production of immature, noninfectious virus particles.9–12 Phase 2 studies of BVM provided proof of concept for this class of agents by demonstrating dose-dependent antiviral activity.7 However, phase 2 development revealed that approximately 50% of patients did not respond to treatment, which was associated with naturally occurring polymorphisms in HIV-1 Gag13 at or near its site of activity.14 GSK3532795 (formerly BMS-955176) is a second-generation MI that also inhibits this single, specific HIV-1 PR cleavage event between CA and SP1 in Gag, producing immature, noninfectious virus particles. However, it exhibits potent activity toward the polymorphic variations in Gag associated with resistance to BVM.15,16

Protease inhibitors (PIs), a widely used class of ARVs, block HIV-1 replication by binding to viral PR, thereby preventing all Gag cleavage events. Clinically, PIs select for PI-resistance mutations that map to viral PR but they can also select for PI-resistance mutations that map to the p7/SP2 and SP2/p6 regions of Gag (amino acids 431–453; hereafter termed “Gag PI-resistance mutations”).17–22 Although sites for Gag PI-resistance mutations are distinct from those reported for BVM,23–26 there have been conflicting reports about the prevalence of BVM resistance–associated Gag polymorphisms in patients on PI therapy.17,24,27,28 Although GSK3532795 has demonstrated potent in vitro activity toward HIV-1 strains containing BVM resistance–associated Gag polymorphisms,16 there is still a need to rigorously determine the sensitivity of PI-resistant viruses to GSK3532795. This will also be clinically relevant for the use of GSK3532795 in patients with PI-treatment experience or failure.

In this first detailed study examining possible cross-resistance between MI and PI ARVs, we investigated whether the acquisition of PI resistance altered GSK3532795 sensitivity. Two sets of highly PI-resistant HIV-1 clinical isolates were investigated. PR only (nonlongitudinal isolates) or PR and Gag (longitudinal isolates, PR and Gag genes derived from patients who were PI-naive at baseline but acquired PI resistance while on PI therapy) were transferred into a laboratory backbone virus for antiviral testing. Here, we report that GSK3532795 maintains antiviral activity against PI-resistant isolates with emergent PR and/or Gag mutations, thus supporting its continued development in treatment-experienced patients regardless of previous PI therapy.



GSK3532795, BMS MI A, BMS MI B, and atazanavir (ATV) were prepared at Bristol-Myers Squibb. BMS MI A and B were evaluated as they are structurally related to GSK3532795, allowing for a determination of the generality of the overall response of PI-resistant isolates to MIs beyond GSK3532795. Darunavir (DRV) and lopinavir (LPV) were purchased and purified from commercial sources.

Cells and Viruses

MT-2 and HEK 293T cells, and the proviral DNA clone of NL4-3 were obtained from the NIH AIDS Research and Reference Reagent Program. Cell lines were subcultured twice a week in either RPMI 1640 (MT-2) or DMEM (HEK 293T) media supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin G, and 100 μg/mL streptomycin.15 The proviral plasmid pNLRepRluc was constructed at Bristol-Myers Squibb from the proviral NL4-3 clone and contained Renilla luciferase in place of the viral nef gene.15

The Gag/PR regions from longitudinal clinical isolates were originally amplified by reverse transcriptase–polymerase chain reaction (PCR). All amplicons were sequenced and, in cases in which cloning and/or assay failures at Monogram Biosciences precluded phenotypic analysis, longitudinal amplicons were reamplified and the Gag/PR regions cloned into pNLRepRluc for evaluation in the Bristol-Myers Squibb multiple- or single-cycle assays (described in section “Susceptibility Assays Performed at Bristol-Myers Squibb”).

A set of nonlongitudinal clinical isolates containing multiple PI-resistance mutations29 was analyzed for sensitivity to GSK3532795, BMS MI B, LPV, and ATV in the multiple-cycle assay. Isolates [NL4-3 background, PI-resistance mutations in PR, wild-type NL4-3Gag] were obtained from Dr. Robert Shafer (Stanford University) through the NIH AIDS Research and Reference Reagent program, and the Gag/PR regions cloned into NLRepRluc.

Drug Susceptibility Assays

Susceptibility Assays Performed at Monogram Biosciences

Monogram Biosciences performed susceptibility assays using the PhenoSense HIV-1 Gag/PR assay (hereafter called the Monogram assay), which is a pseudotype-based, single-cycle assay.30 DRV was chosen as the representative PI to test susceptibility of the isolates. Recombinant virus stocks [pseudotyped with amphotropic murine leukemia virus env proteins] were produced by cotransfecting HEK 293T cell cultures with amphotropic murine leukemia virus env and pHIVluc-resistance test vectors. Viral stocks were deposited in 96-well plates containing serial dilutions of PIs spanning an empirically determined range for each drug. Viral stocks were harvested approximately 48 hours after transfection and used to inoculate fresh HEK 293T cell cultures. Replication was monitored by measuring luciferase expression in the infected target HEK 293T cells ∼72 hours after infection.

Drug susceptibility data were determined by plotting the percent inhibition of luciferase activity versus log10 drug concentration.15 The fold-change in drug susceptibility (FC-IC50) was determined by dividing the drug concentration leading to 50% viral inhibition (IC50) values for the Gag/PR recombinant virus by those of a drug-sensitive reference virus containing the Gag/PR sequences of NL4-3.

Susceptibility Assays Performed at Bristol-Myers Squibb

Single-cycle pseudotype–based (hereafter called the single-cycle assay) and multiple-cycle susceptibility assays were performed at Bristol-Myers Squibb. ATV and LPV were chosen as the representative PIs to test susceptibility of the isolates. For the single-cycle assay, 10 μg of full-length pNLRepRuc variant (containing Gag/PR genes from clinical isolates) and 8 μg of plasmid SV-A-MuLV-env were cotransfected into HEK 293T cells in T75 flasks using a calcium precipitation method (Thermo Fisher Scientific). Transfected cells (100 μL) were seeded onto 96-well plates which contained 100 μL of compound dilutions and after ∼30 hours, 100 μL of supernatant (containing newly produced virus) was transferred to freshly cultured HEK 293T cells and maintained for 2 days. Cell-associated Renilla luciferase activity was measured by the addition of EnduRen Live Cell Substrate (Promega). For multiple-cycle assays, MT-2 cells were infected with pooled full-length virus-containing Gag/PR genes from clinical isolates in the pNLRepRuc backbone versus wild-type control virus. Cell–virus mixtures were seeded onto 96-well plates containing serially diluted compounds. After 4 days' incubation at 37°C/5% CO2, virus growth was determined by measuring the activity of cell-associated Renilla luciferase as described above.

Longitudinal isolates (pre- and post-PI treatment) were obtained from 15 patients receiving PIs as part of their combination ARV therapy regimen for a median (range) of 6 (2.3–11.7) years (Table 1). There were 21 post-PI treatment samples collected while patients were on PI therapy (9 patients had 1 post-treatment sample and 6 patients had 2 post-PI treatment samples). Cloning of Gag/PR amplicons from all 15 patients was performed by Monogram Biosciences. However, only samples from Pts02, 03, 04, 06, 07, 09, 10, 11, 12, 14, and 15 produced pooled clones that could be analyzed for phenotypic sensitivity to GSK3532795 and a clinically relevant PI (DRV). Some pre- or post-PI treatment samples, or both, from Pts01, 05, 06, 08, and 16 yielded a nonreportable result from the Monogram assay but were recloned at Bristol-Myers Squibb and analyzed for phenotypic susceptibility to GSK3532795, BMS MI A and BMS MI B, and 2 clinically relevant PIs (ATV and LPV). For samples in which a potentially elevated GSK3532795 susceptibility was identified by the Monogram assay [changes from baseline (CFB) >3-fold], additional cloning and re-analysis was performed using the single- and multiple-cycle assays (Supplemental Digital Content, Fig. 1 and Table 2

Treatment History, Genotype, and Predicted Phenotypic Susceptibility of all Longitudinal Samples

Assay Interpretation

All phenotypic data from longitudinal isolates were expressed as CFB and calculated as the ratios of post- to pre-PI treatment FC-IC50 values (data not shown). Based on similar phenotyping assays (eg, Monogram Biosciences PhenoSense Entry assay), CFB values ≤3 were considered within the “no-effect” range, and CFB values >3 were considered to be indicative of an effect on susceptibility.31 The relevance of this CFB cut-off in predicting GSK3532795 clinical efficacy is yet to be determined.


Phenotypic Susceptibilities of Highly Resistant PR Genes to GSK3532795: Nonlongitudinal Isolates

Consistent with their genotypic profiles, NLRepRluc proviruses expressing PR genes from a panel of 7 publicly available HIV-1 viruses containing multiple major and minor primary PI resistance-associated mutations (RAMs) were resistant to LPV (FC-IC50 range 15–442) and ATV (FC-IC50 range 11–415), but retained susceptibility to GSK3532795 and BMS MI B, with FC-IC50 values <1 (Supplemental Digital Content, Table 1 A virus with the A364V Gag substitution was used as a positive control for reduced GSK3532795 susceptibility.15 These data clearly indicate that highly PI-resistant viruses with PI RAMs in PR retain sensitivity to GSK3532795 and to a second structurally-related BMS MI (MI B).

Genotypic and Phenotypic Characteristics of Highly Resistant PR and Gag Genes: Longitudinal Isolates

Gag and PR genes from longitudinal isolates from 15 PI-resistant patients were cloned into recombinant virus vectors. Baseline (pre-PI treatment) samples, except those from patient 10 (Pt10), which contained a D30N mutation, contained no major PI RAMs. Conversely, all post-PI treatment samples had major PI RAMs in PR (Table 1) and 16/27 samples had PI-resistant mutations in Gag (at amino acid positions 128, 431, 436, 437, 449, 452, and 453)17–22 (Table 2, see also Supplemental Digital Content, Fig. 2, for full sequences of the entire Gag/PR region). In several patient samples (Pts06, 07, 09, and 15; Tables 2 and 3), changes were acquired in Gag at or near the purported site of action of MIs (near the CA/SP1 cleavage site).17,32 Ten of the 27 pre- or post-PI treatment samples had polymorphisms at Gag amino acids 362, 369, or 370, which are associated with BVM resistance.5,13,14,17,27,31,33–35 The phenotypic susceptibilities of these samples to 8 commonly used PIs [ATV, DRV, LPV, saquinavir (SQV), tipranavir (TPV), fosamprenavir (FPV), indinavir (IDV), and nelfinavir (NFV)] were predicted based on their PR genotype using the Stanford HIV Database Genotypic Resistance Interpretation Algorithm (Table 1). Pre-PI treatment samples from 14/15 patients were predicted to be either completely susceptible or exhibit only low resistance to all 8 PIs. Based on its D30N mutation, the sample from Pt10 was predicted to be susceptible to 7 PIs but highly resistant to NFV. All post-PI treatment samples were predicted to have intermediate/high resistance to ≥3 PIs.

Longitudinal Isolates (Monogram Assay): GSK3532795 and DRV Phenotypic Susceptibility, and Gag Genotype
Longitudinal Isolates (Single- and Multiple-Cycle Assays): GSK3532795 and PI Phenotypic Susceptibility, and Gag Genotype*

Phenotypic Susceptibilities of All Longitudinal Isolates to GSK3532795

All pre- and post-PI treatment samples from 15 patients were analyzed by Monogram Biosciences for phenotypic susceptibility to GSK3532795 and DRV. The Monogram assay successfully reported results for at least 1 post-PI therapy time point from 11/15 patients (Pts02, 03, 04, 06, 07, 09, 10, 11, 12, 14, and 15). For Pt06, results were reported from the pre-PI treatment and only the second of 2 post-PI treatment samples. As shown in Figure 1, major PI RAMs were associated with a 1.9–4.37-fold increase in the median DRV CFB in post-PI treatment samples. The FC-IC50 median (range) was 1.19 (0.67–2.84) for pre-PI treatment samples and 2.72 (0.39–13.00) for post-PI treatment (FC-IC50 data not shown in Fig. 1). Although none of the samples had FC-IC50 >90, indicating clinically defined DRV resistance, the second post-PI treatment sample from Pt09 showed intermediate DRV resistance (FC-IC50 = 13). GSK3532795 susceptibility was observed in 9/11 pre-PI treatment samples, whereas low susceptibility to GSK3532795 was observed in the other 2 patients (FC-IC50 Pt11: 22.30; Pt14: 256.82). The determinants for reduced GSK3532795 susceptibility are currently being further examined in these samples and are not yet understood. However, the corresponding post-PI treatment samples had greatly reduced FC-IC50, indicating enhanced susceptibility. Overall, although no consistent change was observed in the distribution of the GSK3532795 FC-IC50s within this set, the distribution of the GSK3532795 FC-IC50s in post-PI treatment samples indicates that the presence of major PI RAMs did not reduce GSK3532795 susceptibility (Table 2 and Fig. 1).

Longitudinal isolates (Monogram assay): change from baseline in (A) DRV and (B) GSK3532795 susceptibilities*. Pre- and post-treatment longitudinal samples were analyzed using the Monogram PhenoSense Gag/PR assay to determine their susceptibility to DRV and GSK3532795. CFB were calculated as a ratio of post-treatment and pre-treatment FC-IC50s. For a subset of subjects, 2 sets of PTx samples were available. Median (range) and mean (SEM) of the CFB FC-IC50 for the 2 sets of PTx samples are shown in tables under each graph.*All posttherapy samples contain ≥1 major PI RAM (Monogram assay data). CFB, (FC-IC50 post-PI therapy/FC-IC50 pre-PI therapy); FC-IC50, fold-change in IC50; IC50, drug concentration leading to 50% viral inhibition; PI, protease inhibitor; PTx, post-PI treatment; RAM, resistance-associated mutation; SEM, standard error of the mean.

GSK3532795 and DRV susceptibilities of patient samples with reportable results from the Monogram assay were calculated as CFB (Table 2 and Fig. 1). Median CFB for DRV was generally >3 and increased in the 6 patients with multiple post-PI treatment samples from the first (median CFB = 1.92) to the second (median CFB = 4.37) sample, suggesting decreasing drug susceptibility with greater PI treatment experience (Fig. 1 and Table 2). These observations are consistent with the genotype data (Table 1), which show that in patients with multiple post-PI treatment samples, predicted resistance to one or more PIs increases from the first to the second sample. Median CFB for GSK3532795 was ∼1, suggesting minimal change for both the first (median CFB = 0.6) and second (median CFB = 1.33) sets of post-PI treatment samples. However, one of each of 2 time point samples from Pt04 and Pt09 had GSK3532795 CFB >3 (further analysis of these samples is presented in section “Further Analysis of Longitudinal Isolates With GSK3532795 CFB >3”). Conversely, samples from Pts11, 14, and 15 seemed to show increased susceptibility to GSK3532795 compared with pre-PI treatment (CFB <0.33) (Table 2). The genotype data indicate that these samples had intermediate or high predicted resistance to all PIs except DRV (Table 1).

Samples from patients with nonreportable results (Pts01, 05, 06, 08, and 16) using the Monogram assay were recloned and analyzed using the single-cycle assay for phenotypic susceptibilities to GSK3532795, BMS MI A and BMS MI B, and the clinically relevant PIs LPV and ATV. Pt10 samples were used as a control for cross-comparison purposes. The presence of major PI RAMs in 5 post-PI treatment samples from 4 of these patients was associated with ATV and/or LPV CFB values >3, indicative of PI resistance (Table 3, Supplemental Digital Content, Fig. 2, The exception was Pt08, whose major RAM was D30N (characteristic of NFV resistance) and thus still showed susceptibility to ATV and LPV. All post-PI treatment samples had CFB <3 for GSK3532795, BMS MI A, and MI B CFB (Table 3, Supplemental Digital Content, Fig. 2, In summary, analysis of these longitudinal samples demonstrates a lack of cross-resistance to GSK3532795 in the presence of high-level PI resistance and PI treatment-induced mutations in Gag. The observation of sensitivity to MIs A and B further generalizes this result of lack of cross-resistance of MIs to PR-resistant isolates (Table 3, Supplemental Digital Content, Fig. 2,

Further Analysis of Longitudinal Isolates With GSK3532795 CFB >3

The first and second post-PI treatment samples from Pts09 and 04, respectively, had GSK3532795 CFB values substantially >3, and were subsequently recloned and tested using both single- and multiple-cycle assays. The first post-PI treatment sample from Pt09 showed GSK3532795 CFB ∼1.5 in both assays. The second post-PI treatment sample from Pt04 reproduced a CFB >3 (4.17, n = 2 independent experiments) in the single-cycle assay and CFB <3 (2.1) in the multiple-cycle assay. Both were resistant to ATV and/or LPV in the single-cycle assay (Pt04 time point 2 FC-IC50: ATV = 402; LPV = 152; Pt09 time point 1 FC-IC50: ATV = 14.8; LPV = 9.6) and the multiple-cycle assay (Pt04 time point 2 FC-IC50: ATV = 217, LPV = 133; Pt09 time point 1 FC-IC50: ATV = 4.4, LPV = 5.1) (Supplemental Digital Content, Table 2, Thus, the data suggest that the post-PI treatment samples from Pt04 and Pt09 did not exhibit a significant CFB toward GSK3532795.

Impact of PI-Resistance Mutations in Gag Cleavage Sites on GSK3532795 Susceptibility

The most frequently observed mutations in the Gag polyprotein shown to affect PI susceptibility are in MA/CA (codon 128), NC/SP2 (codons 431, 436, and 437), and SP2/P6 (codons 449, 452, and 453).17–22 None of these mutations map to amino acids associated with BVM susceptibility.35 Among the samples analyzed using the Monogram assay, ≥1 Gag PI-resistance mutation (except for a change in codon 452) was present in ≥1 post-PI treatment sample from 10/11 patients. Although samples with Gag PI-resistance mutations had a wider range of GSK3532795 CFB values, median values were similar regardless of the presence of these mutations. In contrast, median DRV CFB values were higher when Gag PI-resistance mutations were present (median CFB = 2.94) than not (median CFB = 1.26) (Fig. 2). Samples analyzed using the single- or multiple-cycle assays had ≥2 Gag PI-resistance mutations in 4/5 patients (excluding Pt08) (Table 1). GSK3532795, BMS MI A, and BMS MI B CFB values for these samples were similar regardless of the presence of these mutations.

Effect of Gag PI-resistance mutations on susceptibility to (A) DRV and (B) GSK3532795. Pre- and post-treatment longitudinal samples were analyzed using the Monogram PhenoSense Gag/PR assay to determine their susceptibility to DRV and GSK3532795. CFB were calculated as a ratio of the post-treatment and pretreatment FC-IC50s. Posttreatment samples with and without secondary PIR mutations in Gag were categorized into 2 groups with “Yes” and “No” flags, respectively. Median (range) values of the CFB FC-IC50 for the 2 groups are shown in tables under each graph. CFB, change from baseline; DRV, darunavir; FC-IC50, fold-change in IC50; IC50, drug concentration leading to 50% viral inhibition; PIR, protease inhibitor resistance; pt, patient.

Changes in Gag at or near the site of MI action, near CA/SP1, were observed in Pts06, 07, 09, and 15 (Tables 2 and 3). Despite the presence of these Gag changes, some of which have been associated with BVM resistance, and could thus be associated with resistance to other MIs, post-PI treatment samples from these patients remained susceptible to GSK3532795 and other structurally related-MIs.


MIs inhibit the final PR-mediated cleavage event in Gag, between the CA protein and SP1, whereas PIs inhibit all the PR-mediated cleavage steps required for virus maturation. Given the related mechanisms of action of these agents, there is potential for emergent PI RAMS to reduce MI susceptibility. This is the first comprehensive study to examine in detail the potential for cross-resistance between MI and PI ARVs. Using both nonlongitudinal (containing only the PR genes and mutations within) and longitudinal (containing PR and Gag genes and mutations within) clinical isolates from patients with acquired PI resistance, we found no definitive examples of viruses exhibiting reduced susceptibility to GSK3532795 in the presence of baseline or progressive PI resistance. Larger sample sizes will be helpful to support these findings.

Analysis of 7 nonlongitudinal HIV-1 viruses containing highly PI-resistant PR genes with multiple major and minor PI RAMs showed that these mutations were not associated with reduced sensitivity to GSK3532795. In a converse analysis, PI susceptibility was studied in viral isolates that exhibited reduced GSK3532795 sensitivity. As expected, viruses with reduced GSK3532795 susceptibility (FC-IC50 3.3–67) retained susceptibility to DRV, LPV, ATV, and NFV (unpublished data, Bristol-Myers Squibb). These data suggest that previous use of PIs will not affect subsequent use of GSK3532795 in PI–treatment-experienced patients and vice versa.

Pre- and post-PI treatment samples of all longitudinal clinical isolates were genotyped and predictions performed on their susceptibility to 8 PIs. As the patients were PI-naive at baseline, major PI RAMs were not present in most of the pre-PI treatment samples, but were present in all the post-PI treatment samples and associated with a predicted reduction in susceptibility to DRV, ATV, LPV, and a number of other less commonly used PIs. Phenotypic susceptibilities to PIs (DRV, ATV, and LPV) and MIs (GSK3532795, BMS MI A, and BMS MI B) were determined using a combination of Monogram and BMS single- and multiple-cycle susceptibility assays. The Monogram assay reported that longitudinal clinical isolates from 9/11 patients, except the first and second post-PI treatment samples for Pts09 and 04, respectively, retained susceptibility to GSK3532795 even in the presence of major PI RAMs. Pre- and/or post-PI treatment samples from Pts01, 05, 06, 08, and 16 yielded a nonreportable result from the Monogram assay and were thus re-analyzed (BMS single- and multiple-cycle assays). As for the set analyzed by Monogram, despite the high-level PI resistance mediated by PR and Gag RAMs, these samples remained susceptible to GSK3532795.

As the predicted PI-resistance profiles of samples from Pts04 and 09 were similar to others within the same set, further phenotypic analyses were performed to verify the Monogram GSK3532795 results. However, the single- and multiple-cycle assays showed that the first post-PI treatment sample for Pt09 had no significant change in susceptibility (CFB <3) to GSK3532795 and BMS MI A and BMS MI B. The second post-PI treatment sample for Pt04 had variable results: GSK3532795 CFB was >3 using the single-cycle assay but <3 using the multiple-cycle assay. The Monogram and BMS single- and multiple-cycle assays used the same primary PCR product for cloning and, additionally, positive control samples from Pt10 produced the same results from both the Monogram and BMS single-cycle assays. Thus, we speculate that differences in results between the assays might be attributable to small differences in PCR reamplification before cloning or small differences in assay conditions, although this was not formally tested. In summary, this detailed analysis generally showed that samples from Pt04 and Pt09 remained susceptible to GSK3532795.

The impact of PI-resistance mutations near the C-terminus of Gag on GSK3532795 susceptibility was also tested. Median GSK3532795 CFB values were similar in the presence or absence of such Gag PI-RAMs. In addition, 4 PI-resistant, post-PI therapy samples contained changes near the CA/SP1 site, but retained susceptibility to GSK3532795.

The results of this study indicate that GSK3532795, a potent, once-daily, second-generation MI, maintains activity toward clinical isolates from PI-treated patients harboring baseline and/or progressive genotypic and phenotypic PI resistance. Emergent mutations in PR and Gag were not linked to reduced viral susceptibility to GSK3532795. A lack of cross-resistance of GSK3532795 to PI-resistant isolates with primary PI resistance supports the use of PIs and MIs simultaneously or in succession, and supports the continued development of GSK3532795 in treatment-experienced patients with previous PI treatment exposure.


The authors thank Matthew Healy for sharing unpublished studies assessing the prevalence of MI-resistance mutations in PI-resistant viruses from the Los Alamos National Laboratory Database. Editorial support was provided by Sharmin Naaz at MediTech Media and funded by Bristol-Myers Squibb.


1. Barre-Sinoussi F, Ross AL, Delfraissy JF. Past, present and future: 30 years of HIV research. Nat Rev Microbiol. 2013;11:877–883.
2. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2015. Available at: Accessed September 2016.
3. European AIDS Clinical Society. European AIDS Clinical Society Guidelines Version 7.1. 2014. Available at: Accessed September 2016.
4. Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11:363–371.
5. Pettit SC, Lindquist JN, Kaplan AH, et al. Processing sites in the human immunodeficiency virus type 1 (HIV–1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology. 2005;2:66.
6. Wiegers K, Rutter G, Kottler H, et al. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol. 1998;72:2846–2854.
7. Smith PF, Ogundele A, Forrest A, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-O-(3',3'- Dimethylsuccinyl)Betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007;51:3574–3581.
8. Sundquist WI, Krausslich HG. HIV-1 assembly, budding, and maturation. Cold Spring Harb Perspect Med. 2012;2:a006924.
9. Kanamoto T, Kashiwada Y, Kanbara K, et al. Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother. 2001;45:1225–1230.
10. Martin DE, Salzwedel K, Allaway GP. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19:107–113.
11. Salzwedel K, Martin DE, Sakalian M. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev. 2007;9:162–172.
12. Temesgen Z, Feinberg JE. Drug evaluation: bevirimat—HIV Gag protein and viral maturation inhibitor. Curr Opin Investig Drugs. 2006;7:759–765.
13. McCallister S, Lalezari J, Richmond G. HIV-1 Gag Polymorphisms Determine Treatment Response to Bevirimat (PA-457). Proceedings of the XVII International HIV Drug Resistance Workshop; 10–14 June 2008. Sitges, Spain.
14. Li F, Goila-Gaur R, Salzwedel K, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A. 2003;100:13555–13560.
15. Nowicka-Sans B, Protack T, Lin Z, et al. Identification and characterization of a second-generation HIV-1 maturation inhibitor with improved potency, anti-viral spectrum and Gag polymorphic coverage. Antimicrob Agents Chemother. 2016;60:3956–3969.
16. Regueiro-Ren A, Liu Z, Chen Y, et al. Discovery of a second generation HIV-1 maturation inhibitor: BMS-955176. ACS Med Chem Lett. 2016;7:568–572.
17. Verheyen J, Verhofstede C, Knops E, et al. High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. AIDS. 2010;24:669–673.
18. Verheyen J, Litau E, Sing T, et al. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther. 2006;11:879–887.
19. Verheyen J, Knops E, Kupfer B, et al. Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naive patients. J Infect. 2009;58:61–67.
20. Parry CM, Kohli A, Boinett CJ, et al. Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J Virol. 2009;83:9094–9101.
21. Dam E, Quercia R, Glass B, et al. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. Plos Pathog. 2009;5:e1000345.
22. Clavel F, Mammano F. Role of Gag in HIV resistance to protease inhibitors. Viruses. 2010;2:1411–1426.
23. Van Baelen K, Salzwedel K, Rondelez E, et al. Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrob Agents Chemother. 2009;53:2185–2188.
24. Adamson CS, Sakalian M, Salzwedel K, et al. Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat. Retrovirology. 2010;7:36.
25. Nguyen AT, Feasley CL, Jackson KW, et al. The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles. Retrovirology. 2011;8:101.
26. Knapp DJHF, Huang S, Harrigan PR. Stable prevalence of bevirimat-related HIV Gag polymorphisms both before and after HAART exposure. [Abstract] 16th Conference on Retroviruses and Opportunistic Infections; 8–11 February 2009. Montreal, Canada; 2009.
27. Seclen E, Gonzalez MM, Corral A, et al. High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. AIDS. 2010;24:467–469.
28. Malet I, Gimferrer AL, Artese A, et al. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemother. 2014;69:2118–2122.
29. Varghese V, Mitsuya Y, Fessel WJ, et al. Prototypical recombinant multi-protease-inhibitor-resistant infectious molecular clones of human immunodeficiency virus type-1. Antimicrob Agents Chemother. 2013;57:4290–4299.
30. Choe S, Feng Y, Limoli KL. Measurement of maturation inhibitor susceptibility using the PhenoSense HIV assay. 15th Conference on Retroviruses and Opportunistic Infections; February 2–8 2008; Boston, MA. Abstract 880.
31. Ray N, Hwang C, Healy MD, et al. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. J Acquir Immune Defic Syndr. 2013;64:7–15.
32. Margot NA, Gibbs CS, Miller MD. Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat. Antimicrob Agents Chemother. 2010;54:2345–2353.
33. Malet I, Wirden M, Derache A, et al. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients. AIDS. 2007;21:871–873.
34. Lin Z, Cantone J, Protack T, et al. Maturation Inhibitor Mechanistic Studies—Understanding and Modeling Differential Inhibition of Gag Polymorphs. 22nd Conference on Retroviruses and Opportunistic Infections; 23–26 Febuary 2015. Seattle, WA; Abstract 539.
35. Fun A, Wensing AM, Verheyen J, et al. Human immunodeficiency virus Gag and protease: partners in resistance. Retrovirology. 2012;9:63.

HIV-1; maturation inhibitor; GSK3532795; protease inhibitor; cross-resistance; in vitro

Supplemental Digital Content

Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.